MEDICAL FACILITIES CORP (DR.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:DR - CA58457V5036 - Common Stock
15.48 CAD
+0.15 (+0.98%)
Overall DR gets a fundamental rating of 7 out of 10. We evaluated DR against 14 industry peers in the Health Care Providers & Services industry. DR gets an excellent profitability rating and is at the same time showing great financial health properties. DR is valued quite cheap, but it does not seem to be growing. These ratings could make DR a good candidate for value investing.
1. Profitability
1.1 Basic Checks
In the past year DR was profitable.
In the past year DR had a positive cash flow from operations.
Of the past 5 years DR 4 years were profitable.
Each year in the past 5 years DR had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 30.18%, DR belongs to the best of the industry, outperforming 92.86% of the companies in the same industry.
Looking at the Return On Equity, with a value of 94.43%, DR belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
The Return On Invested Capital of DR (15.42%) is better than 92.86% of its industry peers.
DR had an Average Return On Invested Capital over the past 3 years of 16.37%. This is significantly above the industry average of 7.27%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.18% | ||
| ROE | 94.43% | ||
| ROIC | 15.42% |
ROA(3y)8.42%
ROA(5y)6.13%
ROE(3y)25.39%
ROE(5y)18.93%
ROIC(3y)16.37%
ROIC(5y)14.6%
1.3 Margins
DR has a better Profit Margin (31.60%) than 92.86% of its industry peers.
In the last couple of years the Profit Margin of DR has grown nicely.
With an excellent Operating Margin value of 15.59%, DR belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
DR's Operating Margin has been stable in the last couple of years.
DR has a Gross Margin of 63.75%. This is amongst the best in the industry. DR outperforms 85.71% of its industry peers.
In the last couple of years the Gross Margin of DR has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.59% | ||
| PM (TTM) | 31.6% | ||
| GM | 63.75% |
OM growth 3Y-0.97%
OM growth 5Y-1.3%
PM growth 3Y78.64%
PM growth 5Y55.2%
GM growth 3Y-0.53%
GM growth 5Y-0.42%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so DR is creating value.
Compared to 1 year ago, DR has less shares outstanding
The number of shares outstanding for DR has been reduced compared to 5 years ago.
Compared to 1 year ago, DR has an improved debt to assets ratio.
2.2 Solvency
DR has an Altman-Z score of 1.35. This is a bad value and indicates that DR is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.35, DR is in the better half of the industry, outperforming 71.43% of the companies in the same industry.
The Debt to FCF ratio of DR is 2.05, which is a good value as it means it would take DR, 2.05 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of DR (2.05) is better than 92.86% of its industry peers.
A Debt/Equity ratio of 1.02 is on the high side and indicates that DR has dependencies on debt financing.
The Debt to Equity ratio of DR (1.02) is comparable to the rest of the industry.
Although DR does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.02 | ||
| Debt/FCF | 2.05 | ||
| Altman-Z | 1.35 |
ROIC/WACC1.81
WACC8.5%
2.3 Liquidity
A Current Ratio of 1.79 indicates that DR should not have too much problems paying its short term obligations.
The Current ratio of DR (1.79) is better than 100.00% of its industry peers.
A Quick Ratio of 1.67 indicates that DR should not have too much problems paying its short term obligations.
DR has a better Quick ratio (1.67) than 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.79 | ||
| Quick Ratio | 1.67 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 60.81% over the past year.
Looking at the last year, DR shows a very negative growth in Revenue. The Revenue has decreased by -41.68% in the last year.
DR shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.59% yearly.
EPS 1Y (TTM)60.81%
EPS 3Y10.86%
EPS 5Y0%
EPS Q2Q%-23.33%
Revenue 1Y (TTM)-41.68%
Revenue growth 3Y-5.96%
Revenue growth 5Y-3.59%
Sales Q2Q%-20.29%
3.2 Future
The Earnings Per Share is expected to grow by 10.76% on average over the next years. This is quite good.
The Revenue is expected to decrease by -7.10% on average over the next years.
EPS Next Y34.23%
EPS Next 2Y14.43%
EPS Next 3Y10.76%
EPS Next 5YN/A
Revenue Next Year-20.98%
Revenue Next 2Y-10.85%
Revenue Next 3Y-7.1%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
DR is valuated reasonably with a Price/Earnings ratio of 9.44.
DR's Price/Earnings ratio is rather cheap when compared to the industry. DR is cheaper than 92.86% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.61, DR is valued rather cheaply.
DR is valuated reasonably with a Price/Forward Earnings ratio of 9.12.
100.00% of the companies in the same industry are more expensive than DR, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 24.01, DR is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.44 | ||
| Fwd PE | 9.12 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, DR is valued cheaper than 100.00% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, DR is valued cheaply inside the industry as 92.86% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.15 | ||
| EV/EBITDA | 4.47 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
DR has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)0.28
PEG (5Y)N/A
EPS Next 2Y14.43%
EPS Next 3Y10.76%
5. Dividend
5.1 Amount
DR has a Yearly Dividend Yield of 2.35%.
Compared to an average industry Dividend Yield of 1.17, DR pays a better dividend. On top of this DR pays more dividend than 85.71% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 1.87, DR pays a bit more dividend than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.35% |
5.2 History
The dividend of DR decreases each year by -19.91%.
DR has been paying a dividend for at least 10 years, so it has a reliable track record.
DR has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)-19.91%
Div Incr Years1
Div Non Decr Years4
5.3 Sustainability
6.72% of the earnings are spent on dividend by DR. This is a low number and sustainable payout ratio.
DP6.72%
EPS Next 2Y14.43%
EPS Next 3Y10.76%
TSX:DR (12/22/2025, 7:00:00 PM)
15.48
+0.15 (+0.98%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.98%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap279.41M
Revenue(TTM)257.36M
Net Income(TTM)81.33M
Analysts42.22
Price Target16.58 (7.11%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.35% |
Yearly Dividend0.35
Dividend Growth(5Y)-19.91%
DP6.72%
Div Incr Years1
Div Non Decr Years4
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.6%
Min EPS beat(2)-7.54%
Max EPS beat(2)6.33%
EPS beat(4)2
Avg EPS beat(4)3.38%
Min EPS beat(4)-24.98%
Max EPS beat(4)39.71%
EPS beat(8)3
Avg EPS beat(8)-25.78%
EPS beat(12)5
Avg EPS beat(12)32.86%
EPS beat(16)7
Avg EPS beat(16)-103.27%
Revenue beat(2)1
Avg Revenue beat(2)-1.3%
Min Revenue beat(2)-4.5%
Max Revenue beat(2)1.91%
Revenue beat(4)1
Avg Revenue beat(4)-6.39%
Min Revenue beat(4)-18.84%
Max Revenue beat(4)1.91%
Revenue beat(8)3
Avg Revenue beat(8)-3.49%
Revenue beat(12)4
Avg Revenue beat(12)-2.43%
Revenue beat(16)5
Avg Revenue beat(16)-2.23%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)15.63%
EPS NY rev (1m)1.24%
EPS NY rev (3m)1.24%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.91%
Revenue NY rev (1m)1.27%
Revenue NY rev (3m)1.27%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.44 | ||
| Fwd PE | 9.12 | ||
| P/S | 0.79 | ||
| P/FCF | 4.15 | ||
| P/OCF | 3.81 | ||
| P/B | 2.35 | ||
| P/tB | N/A | ||
| EV/EBITDA | 4.47 |
EPS(TTM)1.64
EY10.59%
EPS(NY)1.7
Fwd EY10.97%
FCF(TTM)3.73
FCFY24.12%
OCF(TTM)4.06
OCFY26.21%
SpS19.67
BVpS6.58
TBVpS-0.86
PEG (NY)0.28
PEG (5Y)N/A
Graham Number15.58
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.18% | ||
| ROE | 94.43% | ||
| ROCE | 18.66% | ||
| ROIC | 15.42% | ||
| ROICexc | 19.71% | ||
| ROICexgc | 46.81% | ||
| OM | 15.59% | ||
| PM (TTM) | 31.6% | ||
| GM | 63.75% | ||
| FCFM | 18.99% |
ROA(3y)8.42%
ROA(5y)6.13%
ROE(3y)25.39%
ROE(5y)18.93%
ROIC(3y)16.37%
ROIC(5y)14.6%
ROICexc(3y)21.7%
ROICexc(5y)18.79%
ROICexgc(3y)53.59%
ROICexgc(5y)43.79%
ROCE(3y)19.81%
ROCE(5y)17.76%
ROICexgc growth 3Y35.06%
ROICexgc growth 5Y23.36%
ROICexc growth 3Y18.42%
ROICexc growth 5Y13.1%
OM growth 3Y-0.97%
OM growth 5Y-1.3%
PM growth 3Y78.64%
PM growth 5Y55.2%
GM growth 3Y-0.53%
GM growth 5Y-0.42%
F-Score6
Asset Turnover0.95
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.02 | ||
| Debt/FCF | 2.05 | ||
| Debt/EBITDA | 1.54 | ||
| Cap/Depr | 25.03% | ||
| Cap/Sales | 1.64% | ||
| Interest Coverage | 7.65 | ||
| Cash Conversion | 93.1% | ||
| Profit Quality | 60.09% | ||
| Current Ratio | 1.79 | ||
| Quick Ratio | 1.67 | ||
| Altman-Z | 1.35 |
F-Score6
WACC8.5%
ROIC/WACC1.81
Cap/Depr(3y)47.79%
Cap/Depr(5y)40.36%
Cap/Sales(3y)2.81%
Cap/Sales(5y)2.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.81%
EPS 3Y10.86%
EPS 5Y0%
EPS Q2Q%-23.33%
EPS Next Y34.23%
EPS Next 2Y14.43%
EPS Next 3Y10.76%
EPS Next 5YN/A
Revenue 1Y (TTM)-41.68%
Revenue growth 3Y-5.96%
Revenue growth 5Y-3.59%
Sales Q2Q%-20.29%
Revenue Next Year-20.98%
Revenue Next 2Y-10.85%
Revenue Next 3Y-7.1%
Revenue Next 5YN/A
EBIT growth 1Y-46.1%
EBIT growth 3Y-6.86%
EBIT growth 5Y-4.85%
EBIT Next Year4.19%
EBIT Next 3Y2.12%
EBIT Next 5YN/A
FCF growth 1Y-6.31%
FCF growth 3Y4.28%
FCF growth 5Y3.38%
OCF growth 1Y-24.65%
OCF growth 3Y3.26%
OCF growth 5Y1.55%
MEDICAL FACILITIES CORP / DR.CA FAQ
What is the fundamental rating for DR stock?
ChartMill assigns a fundamental rating of 7 / 10 to DR.CA.
What is the valuation status for DR stock?
ChartMill assigns a valuation rating of 9 / 10 to MEDICAL FACILITIES CORP (DR.CA). This can be considered as Undervalued.
Can you provide the profitability details for MEDICAL FACILITIES CORP?
MEDICAL FACILITIES CORP (DR.CA) has a profitability rating of 8 / 10.
Can you provide the PE and PB ratios for DR stock?
The Price/Earnings (PE) ratio for MEDICAL FACILITIES CORP (DR.CA) is 9.44 and the Price/Book (PB) ratio is 2.35.
Can you provide the dividend sustainability for DR stock?
The dividend rating of MEDICAL FACILITIES CORP (DR.CA) is 5 / 10 and the dividend payout ratio is 6.72%.